Spero Therapeutics, Inc. (NASDAQ:SPRO) – Equities researchers at Oppenheimer issued their Q3 2017 earnings estimates for shares of Spero Therapeutics in a research report issued on Monday. Oppenheimer analyst J. Olson forecasts that the company will earn ($2.17) per share for the quarter. Oppenheimer currently has a “Buy” rating and a $30.00 target price on the stock. Oppenheimer also issued estimates for Spero Therapeutics’ Q4 2017 earnings at ($1.97) EPS, FY2017 earnings at ($7.32) EPS, Q1 2018 earnings at ($2.26) EPS, Q2 2018 earnings at ($1.95) EPS, Q3 2018 earnings at ($2.23) EPS, Q4 2018 earnings at ($3.03) EPS, FY2018 earnings at ($9.48) EPS, FY2019 earnings at ($16.13) EPS, FY2020 earnings at ($18.17) EPS and FY2021 earnings at ($12.97) EPS.

Several other analysts have also issued reports on SPRO. Cowen began coverage on shares of Spero Therapeutics in a research report on Monday. They issued an “outperform” rating on the stock. Stifel Nicolaus began coverage on shares of Spero Therapeutics in a research report on Monday. They set a “buy” rating and a $26.00 price objective on the stock. Finally, Bank of America began coverage on Spero Therapeutics in a report on Monday. They set a “neutral” rating for the company.

Shares of Spero Therapeutics (NASDAQ SPRO) opened at $11.95 on Wednesday. Spero Therapeutics has a fifty-two week low of $10.83 and a fifty-two week high of $15.40.

In other Spero Therapeutics news, CFO Joel Sendek purchased 5,000 shares of the stock in a transaction dated Monday, November 6th. The shares were bought at an average cost of $14.00 per share, with a total value of $70,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Plc Glaxosmithkline bought 428,571 shares of the firm’s stock in a transaction that occurred on Monday, November 6th. The shares were purchased at an average cost of $14.00 per share, for a total transaction of $5,999,994.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 649,356 shares of company stock valued at $9,090,984.

TRADEMARK VIOLATION WARNING: This story was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another site, it was illegally copied and reposted in violation of international copyright laws. The original version of this story can be viewed at https://www.dailypolitical.com/2017/11/30/brokers-set-expectations-for-spero-therapeutics-inc-s-q3-2017-earnings-spro.html.

Spero Therapeutics Company Profile

SmartPros Ltd. is engaged in provision of learning and educational solutions in content areas that target specific markets, including accounting/finance, legal, engineering, securities and insurance. The Company also provides education in banking, finance, taxation, information technology, health and safety, human resources and compliance for the general corporate market.

Earnings History and Estimates for Spero Therapeutics (NASDAQ:SPRO)

Receive News & Ratings for Spero Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.